{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:42:12Z","timestamp":1793954532718,"version":"4.8.0"},"reference-count":49,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Toxicol Pathol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>Adeno-associated virus (AAV)-based vectors are the most frequently used platform for retinal gene therapy. Initially explored for the treatment of loss-of-function mutations underpinning many inherited retinal diseases, AAV-based ocular gene therapies are increasingly used to transduce endogenous cells to produce therapeutic proteins, thus producing site-specific biofactories. Relatively invasive ocular routes of administration (ROA) mean prominent procedure-related in-life, and histopathological findings may be observed with some regularity. Test article-related findings may vary with the ROA and cell populations transduced, with retinal pigmented epithelium (RPE) changes prominent (ranging from pigment alteration through degeneration, with or without associated degeneration of the overlying retina) with subretinal ROA, and more anterior changes (iris, ciliary body) generally observed with the intravitreal ROA. Ocular inflammation is the most frequent finding that occurs nonclinically and in patients, and is particularly pronounced with intravitreal administration. Extraocular findings may be observed in extraocular muscles, regional ganglia, or central visual pathways with multiple ocular ROA. Work is still needed to understand the mechanisms underpinning many of these ocular and extraocular findings. Emerging patient data is helping to clarify both the potential for translating nonclinical findings to predict possible human responses and the applicability of nonclinical biomonitoring methods to the clinical setting.<\/jats:p>","DOI":"10.1177\/01926233241307641","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:21:38Z","timestamp":1735258898000},"page":"506-522","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Pathology Findings and In-Life Correlates in the Nonclinical Development of Adeno-Associated Virus (AAV)-Based Retinal Gene Therapies"],"prefix":"10.1177","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5188-9960","authenticated-orcid":false,"given":"Helen S.","family":"Booler","sequence":"first","affiliation":[{"name":"Novartis, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Typhaine","family":"Lejeune","sequence":"additional","affiliation":[{"name":"Charles River Laboratories Montreal ULC, Senneville, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0512-1170","authenticated-orcid":false,"given":"Oliver","family":"Turner","sequence":"additional","affiliation":[{"name":"Novartis, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-5696","authenticated-orcid":false,"given":"Chandra","family":"Saravanan","sequence":"additional","affiliation":[{"name":"Novartis, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua T.","family":"Bartoe","sequence":"additional","affiliation":[{"name":"Northern Biomedical Research, Norton Shores, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6065-1492","authenticated-orcid":false,"given":"Brad","family":"Bolon","sequence":"additional","affiliation":[{"name":"GEMpath, Inc., Longmont, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,12,26]]},"reference":[{"key":"bibr1-01926233241307641","unstructured":"Adverum Biotechnologies, Inc. Adverum provides update on ADVM-022 and the INFINITY trial in patients with diabetic macular edema. Published July 22, 2021. Accessed December 12, 2024. https:\/\/investors.adverum.com\/press_releases\/news-details\/2021\/Adverum-Provides-Update-on-ADVM-022-and-the-INFINITY-Trial-in-Patients-with-Diabetic-Macular-Edema\/default.aspx."},{"key":"bibr2-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-21356"},{"key":"bibr3-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1177\/01926233231179707"},{"key":"bibr4-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1177\/01926233231213851"},{"key":"bibr5-01926233241307641","unstructured":"Bhardwaj N, Joshi A. Neuroanatomy, Ciliary Ganglion. Treasure Island, FL: StatPearls; 2023. Accessed December 12, 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK553182."},{"key":"bibr6-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1177\/0192623312474865"},{"key":"bibr7-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2023.08.017"},{"key":"bibr8-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1177\/01926233211047562"},{"key":"bibr9-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-821046-8.00005-0"},{"key":"bibr10-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2016.31"},{"key":"bibr11-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100915"},{"key":"bibr12-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1016\/J.OMTM.2022.01.013"},{"key":"bibr13-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00310-6"},{"key":"bibr14-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.10.4.3"},{"key":"bibr15-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1177\/0192623320976095"},{"key":"bibr16-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1177\/0300985817705169"},{"key":"bibr17-01926233241307641","unstructured":"FDA (U.S. Food and Drug Administration). Guidance for industry: preclinical assessment of investigational cellular and gene therapy products. Published 2013. Accessed December 12, 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/preclinical-assessment-investigational-cellular-and-gene-therapy-products."},{"key":"bibr18-01926233241307641","unstructured":"FDA (U.S. Food and Drug Administration). Human gene therapy for retinal disorders. Guidance for industry. Published 2020. Accessed December 12, 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/human-gene-therapy-retinal-disorders."},{"key":"bibr19-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2021.03.016"},{"key":"bibr20-01926233241307641","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S364200"},{"key":"bibr21-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-78364-2"},{"key":"bibr22-01926233241307641","doi-asserted-by":"publisher","DOI":"10.2174\/1874364101004010052"},{"key":"bibr23-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1089\/HUM.2020.167"},{"key":"bibr24-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1177\/01926233211041962"},{"key":"bibr25-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(72)90672-5"},{"key":"bibr26-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1177\/0192623315623265"},{"key":"bibr27-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01842-1"},{"key":"bibr28-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1016\/J.NBD.2023.106250"},{"key":"bibr29-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1016\/J.OMTM.2017.12.001"},{"key":"bibr30-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2018.1430136"},{"key":"bibr31-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2022.090"},{"key":"bibr32-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1097\/IIO.0000000000000368"},{"key":"bibr33-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1177\/0192623320967279"},{"key":"bibr34-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.295"},{"key":"bibr35-01926233241307641","unstructured":"Okonkwo ON, Tripathy K. Ocular Hypotony. Treasure Island, FL: StatPearls; 2024. Accessed December 12, 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK582144\/."},{"key":"bibr36-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1177\/0192623316642527"},{"key":"bibr37-01926233241307641","unstructured":"Pieramici D. ADVM-022 intravitreal gene therapy for neovascular AMD: phase 1 OPTIC study. Presentation at the annual meeting of the American Society of Retina Specialists, San Antonio, TX, October 8-12, 2021. Accessed December 12, 2024. https:\/\/adverum.com\/wp-content\/uploads\/2022\/03\/OPTIC-ASRS-Meeting-10-11-2021a.pdf."},{"key":"bibr38-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1111\/CTS.13480"},{"key":"bibr39-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1293\/tox.31.97S"},{"key":"bibr40-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1002\/9780470939956.ch24"},{"key":"bibr41-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2021-321023"},{"key":"bibr42-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31868-8"},{"key":"bibr43-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJCARD.2023.131617"},{"key":"bibr44-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2019.144"},{"key":"bibr45-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1089\/HUM.2021.255"},{"key":"bibr46-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2022.222"},{"key":"bibr47-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1016\/J.YMTHE.2006.05.009"},{"key":"bibr48-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1821000116"},{"key":"bibr49-01926233241307641","doi-asserted-by":"publisher","DOI":"10.1016\/J.PRETEYERES.2013.07.001"}],"container-title":["Toxicologic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/01926233241307641","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/01926233241307641","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/01926233241307641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T16:43:41Z","timestamp":1777653821000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/01926233241307641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1177\/01926233241307641"],"URL":"https:\/\/doi.org\/10.1177\/01926233241307641","relation":{},"ISSN":["0192-6233","1533-1601"],"issn-type":[{"value":"0192-6233","type":"print"},{"value":"1533-1601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}